METHODS AND DEVICES EMPLOYING VAP-1 INHIBITORS

• US 20080058922A1
• Filed: 08/31/2006
• Published: 03/06/2008
• Est. Priority Date: 08/31/2006
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Stolen, Craig
• Application Number:
  US11/469,064
• Publication Number:
  US 20080058922A1
• Time in Patent Office: Days
• US Class Current: 623/1.42
• CPC Class Codes: C07D 263/18 Oxygen atoms

Abstract

An implantable device which employs inhibitors of VAP-1, e.g., inhibitors that reversibly or irreversibly bind to VAP-1, and methods of using the devices is provided.

Claims

1. An implantable device for treating living tissue, comprising:

an intravascular device; and

a composition comprising one or more agents incorporated into at least a portion of the intravascular device, wherein the one or more agents comprise a vascular adhesion protein-1 (VAP-1) inhibitor.

2. The device of claim 1 wherein the intravascular device comprises a transvenous lead.

3. The device of claim 1 wherein the intravascular device comprises a stent.

4. The device of claim 1 wherein the one or more agents comprise a semicarbazide sensitive amine oxidase (SSAO) inhibitor.

5. The device of claim 1 wherein the one or more agent is a sustained release formulation.

6. The device of claim 1 wherein the agent comprises a hydrazine.

7. The device of claim 1 wherein the agent comprises an arylalkylamine.

8. The device of claim 1 wherein the agent comprises a propenylamine.

9. The device of claim 1 wherein the agent comprises a proparyl amine.

10. The device of claim 1 wherein the agent comprises an oxazolidinone.

11. The device of claim 1 wherein the agent comprises a haloalkylamine.

12. A method to inhibit or treat inflammation, restenosis, or oxidative stress in a mammal, comprising introducing to a mammal in need thereof an implantable device comprising a composition comprising an effective amount of one or more agents incorporated into at least a portion of the implantable device, wherein the one or more agents comprise a vascular adhesion protein-1 (VAP-1) inhibitor.

13. The method of claim 12 wherein the agent comprises a hydrazine.

14. The method of claim 12 wherein the agent comprises an arylalkylamine.

15. The method of claim 12 wherein the agent comprises a propenylamine.

16. The method of claim 12 wherein the agent comprises a proparylamine.

17. The method of claim 12 wherein the agent comprises an oxazolidinone.

18. The method of claim 12 wherein the agent comprises a haloalkylamine.

19. The method of claim 12 wherein the mammal is a human.

20. The method of claim 12 wherein the mammal has diabetes.

21. The method of claim 12 wherein the implantable device is a intraluminal device including at least a portion configured to be placed in a body lumen.

22. The method of claim 21 wherein the intraluminal device is a stent.

23. The method of claim 21 wherein the intraluminal device is an intravascular device.

24. The method of claim 12 wherein the composition comprises a sustained release formulation.

25. The method of claim 12 wherein the amount is effective to inhibit or treat inflammation.

26. The method of claim 12 wherein the amount is effective to inhibit or treat restenosis.

27. The method of claim 12 wherein the amount is effective to inhibit or treat oxidative stress.